FDA Approves Amgen's Panitumumab to Treat Advanced Colon Cancer

Publication
Article
OncologyONCOLOGY Vol 20 No 11
Volume 20
Issue 11

Following priority review, the US Food and Drug Administration (FDA) has approved Amgen Inc's panitumumab (Vectibix) for the treatment of advanced colon cancer.

Following priority review, the US Food and Drug Administration (FDA) has approved Amgen Inc's panitumumab (Vectibix) for the treatment of advanced colon cancer. The drug is the first entirely human monoclonal antibody for the treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal cancer after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Better-Than-Expected Results

Panitumumab received an accelerated approval after showing effectiveness in slowing tumor growth and, in some cases, reducing the size of the tumor, the FDA said in a statement. The approval was based on a progression-free survival endpoint. A pivotal trial also showed that patients treated with panitumumab showed a better-than-expected 46% decrease in the rate of tumor growth vs those who received supportive care.

As part of the approval, Amgen committed to conduct a postmarketing trial to show whether the drug improves patients' survival in patients with fewer prior chemotherapies, the FDA said.

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content